Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies
- 1 July 2009
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 30 (7), 550-557
- https://doi.org/10.1097/mnm.0b013e32832bdc80
Abstract
The aim of this prospective study was to assess the influence of different normalization procedures on relative changes in standardized uptake values (SUV) of F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the assessment of chemotherapy response in patients with colorectal carcinoma (CRC) and nonsmall cell lung carcinoma (NSCLC). In 97 patients with CRC (n = 48) and NSCLC (n = 49), FDG-PET was performed before and during the course of chemotherapy. Relative changes in SUV (DeltaSUV) were determined after correction for injected dose and bodyweight, lean body mass, body surface area or a combination of bodyweight and plasma glucose. The predictive value for overall and progression-free survival with respect to the different normalized DeltaSUVs was assessed. In both CRC and NSCLC, no differences were seen in the degree of change between the four SUV-normalizations during chemotherapy. Cox regression analysis for overall survival showed significant hazard ratios of 1.14-1.16 per 10% SUV change in CRC and 1.10-1.13 in NSCLC and for progression-free survival hazard ratios of 1.15 per 10% DeltaSUV change in CRC and 1.10-1.12 in NSCLC. Relative changes in SUV is a strong predictor for survival in both CRC and NSCLC. None of the four normalization methods showed statistical advantage over the other. Therefore, simplifying the methods for analysis of FDG-PET data can improve the incorporation of FDG-PET in clinical treatment-response monitoring and may facilitate application in multicentre trialKeywords
This publication has 30 references indexed in Scilit:
- Chemotherapy response evaluation with FDG–PET in patients with colorectal cancerAnnals of Oncology, 2007
- Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung CancerJournal of Nuclear Medicine, 2007
- Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancerCancer, 2007
- Prediction of Short-term Survival in Patients with Advanced Nonsmall Cell Lung Cancer Following Chemotherapy Based on 2-Deoxy-2-[F-18]fluoro-d-glucose-Positron Emission Tomography: A Feasibility StudyMolecular Imaging & Biology, 2007
- The expanding role of PET technology in the management of patients with colorectal cancerAnnals of Oncology, 2007
- The Role of Positron Emission Tomography in the Management of Recurrent Colorectal Cancer: A ReviewDiseases of the Colon & Rectum, 2007
- FDG-PET for prediction of survival of patients with metastatic colorectal carcinomaAnnals of Oncology, 2006
- Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic reviewThe Lancet Oncology, 2004
- Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003